Passage Bio, Inc. - Common Stock (PASG)

Competitors to Passage Bio, Inc. - Common Stock (PASG)

Audentes Therapeutics, Inc.

Audentes Therapeutics, specializing in gene therapy for rare diseases, competes directly with Passage Bio by focusing on similar therapeutic areas and leveraging adeno-associated virus (AAV) technology to deliver genetic material to patients. Both companies aim to treat genetic-based diseases using innovative therapies, which puts them in direct competition for research funding, partnerships, and patient clinical trials. Audentes has the advantage of established products in its pipeline and collaborations with larger pharmaceutical companies, giving it a more rounded experience in navigating the regulatory landscape.

Bluebird Bio, Inc. 

Bluebird Bio is another key competitor in the gene therapy ecosystem, focusing on genetic diseases and cancer through its lentiviral vector platform. The company competes with Passage Bio by developing therapies that address similar patient populations and pursues regulatory approvals for its gene therapies. Bluebird's established presence in the market and its strategic partnerships with major pharma companies lend it a considerable advantage over newer firms, including Passage Bio, in navigating the complexities of gene therapy introduction.

CRISPR Therapeutics AG 

CRISPR Therapeutics utilizes its innovative CRISPR/Cas9 gene editing technology, potentially impacting the same disease areas that Passage Bio targets, particularly in rare genetic disorders. The company's pipeline includes a variety of gene therapies that could reach the market faster due to their unique technology. CRISPR's advancements and collaborations, as well as significant funding, give it a competitive edge in the overall space, making it a formidable competitor against Passage Bio’s AAV therapies.

Rocket Pharmaceuticals, Inc. 

Rocket Pharmaceuticals focuses on gene therapies for rare diseases, similar to Passage Bio, and employs AAV technology in its treatment modalities. Both companies are competing for clinical advancements and are working towards bringing their therapeutics to market efficiently. Rocket has shown strong early clinical data and possesses a robust pipeline, giving it an edge in attracting investment and partnerships, although its overall market traction is less pronounced than larger players.

Sarepta Therapeutics, Inc. 

Sarepta Therapeutics also specializes in gene therapies, particularly focusing on Duchenne muscular dystrophy (DMD) and other rare genetic disorders, creating a competitive environment with Passage Bio. Sarepta has a well-developed product pipeline and FDA-approved therapies which position it as a strong player in the gene therapy market. This extensive clinical experience provides it with a competitive advantage over Passage Bio in terms of market trust and initial patient access.